Core Insights - Cencora exceeded Wall Street profit estimates for the first quarter, driven by strong demand for specialty medicines and GLP-1 therapies [1] Company Performance - Cencora reported a profit that surpassed analyst expectations, indicating robust financial health and operational efficiency in the current market [1] Industry Trends - The sustained demand for specialty medicines and GLP-1 therapies highlights a growing trend in the pharmaceutical industry, suggesting potential for continued growth in these segments [1]

Exhibit 99.1 CENCORA REPORTS FISCAL 2026 FIRST QUARTER RESULTS Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaf irmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology CONSHOHOCKEN, PA, February 4, 2026 - Cencora, Inc. (NYSE: COR) reported that in its fiscal year 20 ...

Form 10-K for the fiscal year ended September 30, 2025 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.CENCORA, INC.FINANCIAL SUMMARY(in thousands, except per share data)(unaudited)Three MonthsEndedDecember 31, 2025% ofRevenueThree MonthsEndedDecember 31, 2024% ofRevenue%ChangeRevenue$85,932,01 ...

Core Insights - Cencora, Inc. is identified as a strong healthcare stock for 2026, with Morgan Stanley upgrading its rating from Equalweight to Overweight and raising the price target to $400 due to its robust position in specialty pharmaceuticals and the upcoming majority acquisition of OneOncology [1][2] Financial Performance and Growth Projections - Analysts have increased Cencora's FY2026 U.S. Healthcare Solutions AOI growth forecast to 10.8% and International AOI growth to 7.0%, leading to an EPS estimate of $17.63, which is slightly above consensus [2] - Following the announcement of credit agreements, Jefferies upgraded Cencora to a Buy from Hold and raised the price target from $330 to $440, citing the company's strong execution and enhanced long-term plans as key investment factors [5] Acquisition Financing - Cencora entered into credit agreements totaling $4.5 billion to finance the acquisition of OneOncology, which includes a $1.5 billion term credit agreement with JPMorgan Chase Bank and a separate $3 billion term loan facility with Citibank [3][4] - The proceeds from these credit agreements will be used for acquisition consideration, debt repayment, and covering related fees and expenses, with funding contingent on the successful completion of the acquisition [4]

Wall Street analysts expect Cencora (COR) to post quarterly earnings of $4.05 per share in its upcoming report, which indicates a year-over-year increase of 8.6%. Revenues are expected to be $85.97 billion, up 5.5% from the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahead of a company's earnings disclo ...

Core Viewpoint - Cencora (COR) is expected to report strong first-quarter fiscal 2026 results, with positive revenue and earnings growth driven by pharmaceutical utilization trends and specialty-focused assets [1][3][7] Group 1: Financial Estimates - The Zacks Consensus Estimate for revenues is $85.97 billion, reflecting a 5.5% increase from the prior-year quarter [2] - The consensus estimate for earnings is $4.05 per share, indicating an 8.6% improvement from the previous year's figure [2] Group 2: Performance Drivers - Cencora's performance is anticipated to be supported by strong drug volumes and the U.S. Healthcare Solutions segment, which is expected to be the primary earnings driver [3][5][7] - The integration of Retina Consultants of America (RCA) is likely to contribute positively to sales and margins [3][4] Group 3: Segment Analysis - The U.S. Healthcare Solutions segment is projected to generate sales of $76.72 billion, benefiting from specialty distribution and MSO platforms [6][7] - The International Healthcare Solutions segment is expected to maintain growth, with sales estimated at $7.45 billion, supported by stable trends in Europe and World Courier momentum [6][8] Group 4: Margin and Growth Outlook - Margin performance is expected to remain favorable due to mix benefits from specialty distribution and MSO-related services, despite higher interest expenses from acquisition financing [4][5] - Specialty utilization, particularly in Part B drugs, is anticipated to support above-trend operating income growth [5]

Upgrades Summary - Barclays upgraded Zillow Group (ZG) to Equal Weight from Underweight with a price target of $72, increased from $66, citing that significant downside risks are already reflected in the stock price [2] - Rosenblatt upgraded Fortinet (FTNT) to Buy from Neutral with a price target of $100, up from $85, based on positive channel checks indicating a "meaningful inflection" in demand ahead of the Q4 report on February 5 [2] - Benchmark upgraded Littelfuse (LFUS) to Buy from Hold with a price target of $360, following a strong Q4 report and an optimistic outlook as demand improves across the business [2] - Morgan Stanley upgraded Cencora (COR) to Overweight from Equal Weight with a price target of $400, up from $361, highlighting the company's leadership in specialty markets, which will be enhanced by the acquisition of a majority stake in OneOncology [2] - Chardan upgraded Korro Bio (KRRO) to Buy from Neutral with a price target of $15 after the analyst day, indicating that the company has "turned the page" [2] - Piper Sandler also upgraded Korro Bio to Overweight from Neutral [2]

Core Viewpoint - Cencora, Inc. has appointed Ellen Cooper as a new independent director, effective January 20, 2026, bringing significant leadership experience from Lincoln Financial and Goldman Sachs [1] Group 1: Leadership Appointment - Ellen Cooper is the Chairman, President, and CEO of Lincoln Financial, indicating her strong leadership background [1] - Prior to her role as CEO, she held positions as Executive Vice President, Chief Investment Officer, and Head of Enterprise Risk and Annuity Solutions at Lincoln Financial, showcasing her extensive experience in investment and risk management [1] - Ms. Cooper's previous experience at Goldman Sachs adds to her qualifications, enhancing the board's expertise [1]

Core Viewpoint - Pharmaceutical distributors, traditionally viewed as low-margin utilities, are evolving, with Cencora (COR) indicating a shift in operational strategy to potentially enhance profitability and service offerings [1] Industry Summary - The pharmaceutical distribution sector has been characterized by low margins, primarily serving the volume-driven needs of the healthcare industry [1] - Cencora has historically operated within this low-margin framework but is now exploring new operational strategies [1]

Core Insights - Cencora is a global pharmaceutical services healthcare company that ships over 1 billion medications annually through its MSO investments [2] - The company reported a 9% year-over-year revenue increase and a 16% increase in both adjusted operating income and adjusted diluted EPS, while generating $3 billion in free cash flow [2] Strategic Focus - Cencora emphasizes its purpose-driven approach, aiming to create healthier futures, which is a key indicator of its operational outcomes [3] - The company is strategically focused on four drivers, including digital transformation, optimizing business processes, and leveraging advanced analytics and AI to enhance business operations [3]